Thromboprophylaxis, Delta SOFA and Main Outcomes in Ventilated Patients: An Analysis of the MIMIC-III Clinical Database

Mrigendra Bastola (✉ mbastola@nih.gov)  
United States National Library of Medicine

Craig Locatis  
United States National Library of Medicine

Paul Fontelo  
United States National Library of Medicine

Research Article

Keywords: Ventilation, Thromboprophylaxis, Delta-SOFA, MIMIC-III Clinical Database.

DOI: https://doi.org/10.21203/rs.3.rs-121520/v1

License: Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Introduction:** Critical care patients are at higher risk for thromboembolic disorders. There are limited studies regarding the effect of Heparin, Warfarin, Enoxaparin and Aspirin on ventilated patients, who are likely to both benefit from prophylaxis and suffer from adverse effects of blood thinners.

**Methods:** This study analyzed the MIMIC-III clinical database on 4192 ventilated patients using Statistical Analysis Software (V9.4). Relevant data was systematically analyzed on the thromboprophylaxis agents and their effects on major treatment outcomes. Parameters studied were the length of ventilation, length of Intensive Care Unit (ICU) stays, ICU mortality, inpatient mortality, improvement in SOFA score (delta SOFA), and occurrence of major thromboembolic events such as pulmonary embolism (PE) and deep venous thrombosis (DVT).

**Results:** Except Aspirin, all thromboprophylactic agents showed statistically significant reduction on ICU mortality. None of the blood thinners showed statistically significant reduction in occurrences of pulmonary embolism and deep venous thrombosis. The treatment groups did not show any significant difference in their baseline SOFA scores among the included ventilated patients (ANOVA, F=2.26, p=0.06). Heparin, Warfarin, Enoxaparin and Aspirin had adjusted Odds ratios of 0.59 (p<0.01, 0.47-0.77), 0.23 (p<0.05, 0.1-0.57), 0.36 (p<0.05, 0.16-0.83) and 0.75 (p=0.15, 0.51-1.1) for ICU mortality. Heparin, Warfarin, Enoxaparin and Aspirin had adjusted Odds ratios of 0.51 (p<0.01, 0.38-0.68), 0.19 (p<0.01, 0.06-0.59), 0.42 (p=0.06, 0.17-1.05) and 0.84 (p=0.43, 0.84-0.54) for overall ventilated patient hospital mortality, including after transfers to the inpatient ward. Only Heparin (p<0.05, OR 1.52 (1.07-2.15)) was associated with thrombocytopenia episodes, which required platelets transfusion. None showed statistically significant relationships with development of thromboembolic events after thromboprophylaxis. Only Heparin had mild effect on improvement in sequential organ failure assessment (delta SOFA) scores at 7 and 10 day after ICU admission (p<0.05, OR 1.17 (1.03-1.32)).

**Conclusion:** Although the results supported the use of thromboprophylaxis in ventilated patients to improve treatment outcomes, no benefits were indicated for using newer blood thinners (Enoxaparin) than older ones (Heparin & Warfarin). Heparin is related to both higher episodes of platelets transfusion and improvement of delta SOFA scores at end of first week of ICU admission. If validated by future research, the findings of this study might help practitioners and researchers to better understand thromboprophylaxis in ventilated patients.

**Introduction**

Thromboprophylaxis drugs are commonly used in critical care settings. Studies have shown that the rate of venous thromboembolism rises from 10 to 80 percent in ICU patients without thromboprophylaxis [1]. ICU patients have a higher risk for thromboembolic events due to immobilization and invasive procedures (intubation, central arterial and venous lines) [1, 2]. Pulmonary embolism is a leading cause of death in critically ill patients [3]. Many studies advocate thromboprophylaxis for patients who are at risk of
developing of thromboembolism [4]. Some studies show that newer blood thinners are better than older, due to lower incidence of adverse effects, such as thrombocytopenia related internal bleeding [5]. Practitioners routinely use coagulation tests (e.g. prothrombin time, activated partial thromboplastin time, international normalized ratio) and platelet counts while monitoring thromboprophylaxis agents. Although coagulation tests guide practitioners to titrate the dose of prophylactic blood thinners or switch to others, these monitoring methods give little insight regarding patient’s course of care or outcomes during ventilation and ICU-related stays.

Due to the many complexities of patient management and ventilation risks, the treatment decisions for ventilated patients are more likely to be influenced by significant ICU-related outcomes, including decisions for thromboprophylaxis. Although studies support the active use of blood thinners in an ICU setting, none are considered entirely safe for ventilated patients, because of increased risks of thrombocytopenia, numerous drug interactions, and major gastrointestinal or other life-threatening bleeding episodes, requiring precise dosing and monitoring [6, 7]. These life-threatening episodes can contribute towards longer ICU stay, bleeding complications, and hospital mortality. Very few publications are available about ICU patients and the safety of thromboprophylaxis that emphasize risks of serious complications. Protocols avoiding traditional thromboprophylaxis such as Heparin and using citrate anticoagulation rather than aiming to reduce bleeding risks have been advocated [8]. Despite thromboprophylaxis, ventilated patients seem to be at higher risk of pulmonary embolism and deep vein thrombosis, and there is lack of data on diagnosis and subsequent management [9, 10].

This study analyzed the effect of the thromboprophylaxis agents on ventilated patient-related outcomes, clinical improvement during ICU stay, and the effectiveness on decreasing major thromboembolic disorders (i.e., Pulmonary Embolism (PE) and Deep Venous Thrombosis (DVT)) and assessed their effects on clinical thrombocytopenia requiring platelets transfusion.

**Methods**

Data for this study were obtained from the publicly available MIMIC-III (Medical Information Mart for Intensive Care III) clinical database containing de-identified data from critical care patients. SQL queries in Python were used to identify all patients who were ventilated and received thromboprophylaxis agents by using ICD-9 codes and generic prescription drug names. Queries included chart events, ICU stays, ICU admissions and prescriptions sections of the MIMIC-III clinical database and compiled all relevant data in a single tabular format output.

The blood thinners studied were, Heparin, Warfarin, Enoxaparin and Aspirin. These medications comprised more than 95% of all blood thinners used in the ventilated ICU patients in the study population. Other thinners, such as Clopidogrel, Fondaparinux and Dipyridamole-Aspirin combination, did not have enough patients to include in the analysis. Any ventilated patient who received blood thinners in standard dosage were included in this study. The authors also excluded Heparin if it was used only as a flushing agent for central or peripheral lines and included patients where its use was of therapeutic significance. In
the included participants, the administered dose of Enoxaparin, Warfarin, Heparin and Aspirin ranged from 30 to 100 units, 1 to 10 mg, 700 to 30000 units and 81 to 325 mg, respectively. In this study, the authors assumed that all such changes in medications, such as increasing or decreasing doses and switching or stopping medications, were taken in accordance with individual patient status, and clinical practice guidelines on thromboprophylaxis. Treatment groups and controls were defined as patients who received thromboprophylaxis in therapeutic dose and those who received none respectively. The authors did not perform any sub-group analysis on medication doses or combination therapy of blood thinners in the ICU.

All ventilated patients in the MIMIC-III clinical database, including those with known thromboembolic disorders, are at potential risk of developing thromboembolism during or after ventilation, were included in this study. The date-ranges for patients were available in MIMIC in de-identified form, and all date-ranges for patients older than 16 years of age were included (Table 1). All ventilated patients in all age ranges were identified in SQL queries, and were included in this study (n = 4192), except entries with missing data. Patients who had ICU stays less than 24 hours were excluded from the study.

Statistical Analysis Software (SAS, version 9.4) was used for data analysis. Regression analysis of survival data based on proportional hazards models was generated for ICU mortality indicators. Survival probability plots were generated for ventilated patients. Odds ratios were calculated for the thromboprophylactic agents and the occurrence of pulmonary embolism and deep venous thrombosis. Primary clinical outcomes reviewed were: length of ventilation, length of ICU stays, ICU mortality, inpatient mortality, SOFA scores, risk of major internal bleeding, and occurrence of major thromboembolic events such as, pulmonary embolism and deep venous thrombosis. The Sequential Organ Failure Assessment (SOFA) and Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) scores are widely used and accepted form of ICU mortality prediction tool. Acute Physiology Score (APS) is a part of APACHE scoring system. Clinical improvement was assessed using a Delta SOFA score, which is defined as the difference between the SOFA scores at baseline (ICU admission) and SOFA scores at the 4th (average ICU stay days), 7th, and 10th day after ICU admission [11]. The effect of the blood thinners on Delta SOFA scores was assessed with the proportional hazard ratios and adjusted Odds ratios using logistic regression. A cumulative hazard ratio for SOFA scores at ICU admission and for length of ventilation was calculated. Logistic regression with confounders adjustment was performed and adjusted odds ratios were derived for ICU mortality, overall hospital mortality and Delta SOFA score.

Results

The median ventilation duration was less than a day (23.5 hours) in 4192 ventilated patients. The study population had a median age of 59 years, 2404 were males and 1788 were females. The median ICU length of stay was 2.84 days while the median hospital stay was 7.48 days. 746 subjects expired in the hospital wards and 588 expired in the ICU. The median survival duration was 40.2 days for all expired patients, and 2.45 days for those who expired during ICU stay. The treatment groups did not show any significant difference in their baseline SOFA scores (ICU day 1) among the included ventilated patients.
(ANOVA test, F-value = 2.26, p-value = 0.06). Moreover, the treatment groups did not show significant differences between baseline (ICU Day 1) Acute Physiologic Assessment and Chronic Health Evaluation (APACHE-III) scores (ANOVA, F = 0.71, p = 0.55) and baseline Acute Physiology Score (APSIII) scores (ANOVA, F = 1.41, p = 0.24). However, this analysis of APACHE scores had substantial limitations/issues and discussed later (section: discussion) and was not pursued further in the final analyses of this study (Table 1).

Other relevant demographic characteristics are listed in Table 1. Of the 4192 ventilated patients, 111 patients were diagnosed with DVT and related conditions, and 70 were recorded as pulmonary embolism related categories in ICD-9. Congestive heart failure was present in 296 ventilated patients, atrial fibrillation in 669, coronary artery disease in 422, renal disorders in 280, liver diseases in 302 and 42 had Chronic Obstructive Pulmonary Disease. 829 had malignancies, 1518 had respiratory failure, one patient had endocarditis, 68 patients had Acute Respiratory Distress Syndrome, and 650 had pneumonia. Of the included patients, 257 were regular alcohol users and 317 were regular smokers or smoke-exposed under ICD-9 categories.

**Thromboprophylaxis use and Survival plot for ventilated patients**

Among those who received either oral or parenteral thromboprophylaxis, 2408 of the ventilated patients received Heparin or its derivatives, 250 patients received Warfarin; 220 patients received Enoxaparin while 653 patients received Aspirin, either alone or in combination (Table 1). 1453 patients received none of the blood thinners and were used as control group (Table 1). Platelets transfusions were given to 157 patients. Clopidogrel was given to 93 patients, while four patients received Fondaparinux. Clopidogrel, Fondaparinux and Dipyridamole-Aspirin combination were excluded from further analysis due to the small sample size. 61.5 percentage (n = 2580 patients) of the ventilated patients received Heparin, Warfarin and Enoxaparin, either alone or in combination. Among the 4192 patients, 225 were tested for D-dimer levels, 25 of them showed D-dimer levels within the normal range (< 500 units). D-dimers levels rapidly increase to higher levels (in thousands) in patients with thromboembolism. Thirty patients had D-dimer levels of 1000–2000 units, while in 170 patients, the levels were more than 2000 units. 288 of the ventilated patients had history of long-term use of anticoagulants prior to ICU admission, which included one or more of the oral anticoagulants (Warfarin and Aspirin).

SOFA scores at ICU admission and the duration of ventilation were positively associated with cumulative hazard (Fig. 1). The survival probability curve showed sharp decreases in the first week and continued decreasing for 10 days of ICU stay, then remained low afterwards (Fig. 1a). Based on the survival curves (Fig. 1a & b), SOFA scores were calculated at the 4th, 7th and 10th day of admission, and changes in the SOFA scores were analyzed relative to use of thromboprophylaxis. Cumulative plots showed mortality rates rising stepwise with SOFA scores at ICU admission (Fig. 2). Predicted cumulative probabilities showed higher SOFA scores having higher predictive values for overall hospital mortality (Fig. 2). DVTs were more likely treated with Warfarin (p < 0.01, OR 4.19, 2.52–6.97) while pulmonary embolism patients
were more likely to receive both Warfarin (p < 0.01, OR 5.06, 2.75–9.3) and Enoxaparin (p < 0.01, OR 3.8, 2.714) during the hospital stay (Table 2).

**Hazard ratios for survival durations, ventilator durations and thromboembolic events**

Aspirin was not significant in any of the outcomes calculated, except for the reduction of ICU stay duration (Tables 2, 3 & 4). Hazard ratio calculations included all ICU stay expired, in-patient stay expired, and discharged patients using regression analysis of data using proportional hazards model. For ICU length of stay, Heparin, Warfarin, Enoxaparin and Aspirin had hazard ratios of 0.59 (p < 0.01), 0.81(p < 0.01), 0.65(p < 0.01) and 0.88 (p < 0.01) respectively. For hospital length of stay, Heparin, Warfarin, Enoxaparin and Aspirin had hazard ratios of 0.7 (p < 0.01), 0.82(p < 0.01), 0.62(p < 0.01) and 0.96(p = 0.38) respectively (Table 3). For ventilation duration, Heparin, Warfarin, Enoxaparin and Aspirin had hazard ratios of 0.66 (p < 0.01), 0.87(p = 0.13), 0.64(p < 0.01) and 0.98(p = 0.59) respectively (Table 3). When data was analyzed for occurrence of major thromboembolic events for each of the blood thinners, none of the blood thinners showed statistically significant reduction in occurrences of pulmonary embolism and deep venous thrombosis, suggesting equivocal effects among Heparin, Warfarin, Enoxaparin and Aspirin (Table 3).

Adjusted odds ratios for ICU mortality, overall hospital mortality, platelets transfusion events and delta SOFAs at day 4, 7 & 10

The main objective of this study is ICU-stay related outcomes (e.g. mortality), hence, confounders for mortality were adjusted (Table 4). The occurrence of thromboembolic episodes, such as PE and DVT, had insufficient case rates in the study population so they were not included as secondary objectives. The confounders used in the study were adopted from a publication on ICU mortality [12]. The analysis was adjusted for confounders age, gender, malignancy, smoking, chronic alcoholism, SOFA score at admission, night shift admissions, night shift deaths, weekend admission and weekend deaths (Table 4) [12]. Except Aspirin, all thromboprophylactic agents showed statistically significant reduction on ICU mortality (Table 4). Heparin, Warfarin and Enoxaparin had adjusted Odds ratios of 0.59(p < 0.01, 0.47–0.77), 0.23(p < 0.05, 0.1–0.57) and 0.36(P < 0.05, 0.16–0.83) for ICU mortality (Table 4). Heparin, Warfarin and Enoxaparin had adjusted Odds ratios of 0.51(p < 0.01, 0.38–0.68), 0.19(p < 0.01, 0.06–0.59) and 0.42(P = 0.06, 0.17–1.05) for overall ventilated patient hospital mortality, including after transfers to the inpatient ward (Table 4).

The major risk of internal bleeding is often assessed by platelet counts. The platelets rich plasma transfusion was taken as a surrogate for the “risky” platelet levels in this study. Logistic regression was chosen for the final analysis of thrombocytopenia (Table 4), which allowed known mortality related confounding factors’ adjustments. Only Heparin (P < 0.05, OR 1.52(1.07–2.15)) was associated with serious thrombocytopenia episodes, which required platelets transfusion (Table 4). Only Heparin had mild effect on improvement in sequential organ failure assessment (delta SOFA) scores at 7 and 10 day after ICU admission (P < 0.05, OR 1.17 (1.03–1.32) (Table 4).
Discussion

Heparin was the most used agent, followed by Warfarin and its derivatives. Heparin, Warfarin, Enoxaparin were associated with shorter length of ICU stays and hospital stays and lower mortality events. These findings suggest that the use of all the thromboprophylaxis agents had comparable effects in ventilated patients and had a significant positive impact on the ICU-related outcomes in the study population. Also, the newer blood thinner, Enoxaparin, had lesser effect on the outcomes, contrary to expectations, and, perhaps, had slightly lower mortality or morbidity advantages compared to the older blood thinners such as Heparin and Warfarin (Table 2 &3). This finding contradicts the findings of a published study where Enoxaparin or Dalteparin were found at least as effective as unfractionated Heparin [13]. This study showed high use of thromboprophylaxis among ventilated patients (61.5%), comparable with other published studies, which reported overall thromboprophylaxis at 61.8% for all indicated patients during a hospital stay [14]. Also, the occurrences of pulmonary embolism, deep venous thrombosis (DVT) during the hospital stay were statistically significant for none of the blood thinners (Table 3). These findings are comparable with those of a previous study which did not find thromboprophylaxis prevents PE [15, 16]. Severe thrombocytopenia is a life-threatening complication, and can potentially cause internal bleeding, (e.g. intracerebral hemorrhage) if not treated. In this study, only Heparin was associated with serious thrombocytopenia episodes which required platelets transfusion (Table 4).

The number of individuals diagnosed with pulmonary embolism (n = 70) and DVT (n = 111) was small. Moreover, the occurrence of either pulmonary embolism or DVT did not vary significantly between any of the blood thinners studied (Table 2 &3). However, DVTs were more likely treated with Warfarin while pulmonary embolism patients were more likely to receive both Warfarin and Enoxaparin during their hospital stay (Table 2). These findings align with the contemporary clinical practice where the individuals who developed PE and DVT during the hospital stay are presumably switched or other thromboprophylactic agents are added. Also, higher D-dimer levels were not significantly associated with any of the blood thinners studied, although some studies have suggested that Heparin use might cause alterations in D-dimer levels (Table 4) [17]. These findings are comparable to findings in a a recently published review article, which included three randomized controlled trials (RCTs) held in ICU patients and concluded that the incidence of DVT was significantly lower in the thromboprophylaxis group in comparison to the control group, irrespective of the type of thromboprophylaxis used [18].

MIMIC-III (Medical Information Mart for Intensive Care III) is a large, freely available database comprised of deidentified health-related data associated with over 40,000 patients admitted in critical care units of the Beth Israel Deaconess Medical Center between 2001 and 2012 [19]. However, there are limitations regarding the history of prior oral anticoagulants use, such as Warfarin. The history of intake of Warfarin or other anticoagulants prior to ICU admission was not sufficiently documented in the database for useful analysis. Only 288 of the 4192 ventilated patients were on long-term anticoagulants prior to their admission, taking either Warfarin, Aspirin, or others. Moreover, no data on adequacy of dose, regularity of intake or their specific doses could be obtained. The study did not include the secondary analyses on patients with previous history of oral anticoagulant because of inadequate sample size and insufficient
data. Furthermore, these patients probably represent patients at higher risk than others since they have two added risk factors for thromboembolism (ventilation and preexisting thromboembolic conditions). In these conditions, the authors had to assume that the practitioners routinely checked coagulation parameters to initiate, switch (oral to injectables), adjust dose or even stop blood thinners (Warfarin) temporarily during ventilation, within hours of their ICU admission. This study assumes all such decisions were properly taken at the ICU admission and stay. In all of the included ventilated patients in our study, the practitioners routinely checked coagulation profiles, which the authors used fair use assumption and did not investigate further in more details. Additionally, ventilated patients with prior use of oral blood thinners (n = 288) might have represented patients with an even higher risk of thrombosis during their ICU stay, when compared to the rest of the ventilated patients (n = 3904), owing to the presence of multiple risk factors for thromboembolism.

The treatment groups did not show any significant difference in their baseline SOFA scores among ventilated patients. Other ICU mortality scoring methods, such as APACHE, were not selected for analysis in this study due to the lack of sufficient and reliable data on their admission diagnosis at the ICU. In contrast, SOFA scores do not need those admission diagnosis parameters. Additionally, unlike the delta-SOFA score, the application of improvement of APACHE score or any other ICU mortality scoring system has not been addressed sufficiently in published literature [11]. The validity of using delta SOFA scores in our study is further supported in survival plots (Figs. 1 and 2), which reveal the association of higher SOFA scores with higher mortality rates. Consequently, SOFA scores and their improvement (delta SOFA) on days 4, 7 and 10 were chosen for analysis in this study. Furthermore, the STROBE statement requirements were fulfilled in this study [20].

Critical care patients are complex in their physiological derangements and often have multiple diagnoses at or after their admission. The comorbidity score also has a major contribution to the APACHE scoring systems. In APACHE, morbidity scores are derived from the presence of chronic comorbidities such as hepatic failure, immunosuppression, lymphoma, leukemia, metastasis, etc. recorded at or within 24 hours of ICU admission, some of which are based on subjective assessment (provisional diagnoses). These admission diagnoses are complex and are not accurately recorded with proper ICD-9 codes in the MIMIC database [21, 22]. In the included patients, only a limited number (n = 169) from admissions records (n = 495) were derived from SQL query reports (‘chartevents’ and ‘admissions’ records sections of the MIMIC database) had an admission diagnosis recorded with extractable ICD-9 code usable for APACHE scores calculation. The authors considered this as insufficient for this study. Likewise, a significant number of the participants (n = 1545) had unreliable or incomplete diagnosis codes (e.g. symptoms such as pain under evaluation, uncertain injury codes, procedures, provisional/suspected/rule-out diagnoses, ambiguous abbreviations, acute conditions such as electrolyte imbalances) recorded as their admission diagnosis in their records, and were recorded without proper ICD-9 codes. Furthermore, while comparing final diagnoses with admission diagnoses, chronic morbidities (such as chronic renal failure, metastasis) were ambiguous and were insufficiently documented at ICU admission day 1 (n = 14), which were more likely to have existed before their ICU admission in the participants [21].
Limitations

A limitation of the study is the paucity of available data and publications on newer blood thinners (e.g. Dabigatran and Fondaparinux) which had low utilization levels in the study population. A more extensive study for these and newer blood thinners might be needed. Irrespective of the decision on thromboprophylaxis (switching, adding or increasing dose), if the blood thinner medication is used in critical care, this study considered it as thromboprophylaxis, and this study included all such cases. Due to complexities in combinations and small sample size, subgroup analysis on combination therapy of blood thinners was not performed. This study included patients of multiple comorbidities with diverse risk factors for the development of thromboembolic events such as, immobilization, sepsis, surgery, multiple organ failures, malignancy and indwelling catheters. A comorbidity/ risk specific study of thromboprophylaxis is desirable in future studies to analyze the choice of the anticoagulants in detail. Also, the study did not include the secondary analyses on patients with previous history of oral anticoagulant use or dosage of anticoagulants because of inadequate sample size and insufficient data. Many comorbidity entries on ICU diagnoses at admission were incomplete and were noted without ICD-9 codes. The ventilated patients included all patients within the critical care unit, so this might have included some patients who were previously prescribed oral anticoagulants because of preexisting morbidities. Moreover, these patients are probably at a higher thromboembolic risk due to presence of two risk factors for development of thromboembolism (ventilation and preexisting conditions). No data on the adequacy of dose, regularity of intake or their specific doses could be obtained on prior oral anticoagulant intake, and no further analysis was performed. More in-depth and broader investigations on the risk of bleeding, comorbidities specific, risk stratified, and dosage specific analyses are desirable in future studies.

Conclusion

The findings of this study support the use of thromboprophylaxis with Heparin, Warfarin and Enoxaparin, either alone or in combination, to improve ICU stay outcomes by reducing the duration of hospital and ICU stays, lowering ICU mortality, and reducing ventilator duration. Although the results supported the use of thromboprophylaxis in ventilated patients to improve treatment outcomes and decrease thromboembolic events, this analysis did not show any benefits of newer blood thinners (e.g. Enoxaparin) when compared to older ones (e.g. Heparin and Warfarin) as suggested by some studies. In this study, Heparin was related to both higher episodes of platelets transfusion and improvement of delta SOFA scores at end of first week of ICU admission. If validated by future research, the findings of this study might help practitioners and researchers to better understand thromboprophylaxis in ventilated patients.

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.
Availability of data and materials:

The data used in this review are extracted from publicly available, deidentified MIMIC-III clinical database (URL: https://physionet.org/content/mimiciii/1.4/). Additionally, SQL queries in Python, the deidentified datasets used and data analysis output from SAS are available from the corresponding author upon reasonable request.

Competing interests: Authors declare no competing interests. The authors are grateful for the reviewing the study and his expert opinion on baseline data analysis provided by Dr. Seo Hyon Baik for this study.

Funding:

This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Library of Medicine (NLM) and Lister Hill National Center for Biomedical Communications (LHNCBC). The funding body had no role in the design of the study, data collection, data analysis, interpretation of the findings and writing of the manuscript.

Authors’ contributions:

PF, MB, and CL conceived the idea and design for the paper. MB performed the research on the MIMIC-III clinical database, including data collection and statistical analysis. MB wrote the main draft of the paper, including tables and figures. PF and CL assisted in writing the paper. All of the authors reviewed and approved the final version of the manuscript.

Acknowledgements:

The views and opinions of the authors herein do not necessarily state or reflect those of the National Library of Medicine, National Institutes of Health or the US Department of Health and Human Services.

References


20. STROBE checklist for cohort, case-control, and cross-sectional studies (combined), ISPM - University of Bern. Available from: https://www.strobe-statement.org/?id=available-checklists

21. Vincent Major Y. Reusable Filtering Functions for Application in ICU data: a case study [Internet]. PubMed Central (PMC). 2020 [cited 21 November 2020]. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333239/


Tables

Due to technical limitations, table 1,2,3,4 is only available as a download in the Supplemental Files section.